A hub for independent voices and hard truths
Hims stock price growth 25% since the peptide meeting day is set KEY POINTS Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. Peptides are gaining …
GLP-1 weight-loss drugs are now the center of a federal crackdown. The FDA has begun seizing counterfeit semaglutide and tirzepatide products from the U.S. supply chain. Some vials contained bacterial contamination. Others were mislabeled or chemically altered. The agency confirmed …
A new study just flipped the script on diabetes treatment. Researchers tracked 174,458 patients with type 2 diabetes and found that GLP-1 receptor agonists cut dementia risk more effectively than metformin. The data spans 20 years. The results aren’t subtle. …